Colorado BioScience Association Appoints New Board Leadership

Terumo BCT General Counsel Scott Larson named chairman of the board

DENVER--()--Colorado BioScience Association (CBSA) announces the appointment of Scott Larson as its new chairman of the board of directors. Larson, Senior Vice President of Legal and General Counsel for the global medical device innovator, Lakewood-based Terumo BCT, will lead CBSA for a two-year term. Larson replaces outgoing chair Mark Spiecker, who will continue to serve on the CBSA board and executive committee through 2017.

Joining Larson and Spiecker in executive committee positions are:

Vice Chairman: Ginny Orndorff, Director, CID4
Treasurer: Jim Wilson, Partner, E&Y
Secretary: Alan Rudolph, Ph.D., Vice President for Research, Colorado State University
Membership Chair: Dustin Whistler, Forte Commercial Real Estate
Policy Chair: Dan Wittenberg, Snell & Wilmer

Scott Larson, Chairman of the Board for CBSA, said:
“The Colorado BioScience Association supports our fast-growing sector by focusing efforts on the themes that matter most to our members, including increasing access to capital, highlighting their success stories, and connecting talent within Colorado biosciences. I’m proud to work with our board to directly contribute to the vitality of our bioscience sector.”

The 30-person CBSA board of directors is comprised of representatives from the state’s biotechnology, medical device, diagnostic, pharmaceutical, ag bio, digital health, healthcare and research organizations.

Newly Appointed Board Members:

Frank Segrave, CEO, Silvergate Pharmaceuticals
Christopher Banas, CEO, Bio2 Medical
Chris McDonald, Vice President of Global Biologics – Colorado, AstraZeneca
Shelley Zelin, Vice President Human Resources, Allosource

April Giles, President and CEO of CBSA said:
“Our newest board members, all from commercial companies, represent a shift in our state’s bioscience sector. While Colorado is known for a thriving start-up community, several of our companies are moving from the emerging or mid-stage into the manufacturing stage. We’re pleased to welcome leaders from Silvergate Pharmaceuticals, Bio2Medical, AstraZeneca and Allosource to the Colorado Bioscience Association Board of Directors.”

Board members commit to a three-year term and work in partnership with CBSA staff to support the growth of Colorado’s more than 720 bioscience companies. Names and biographies of the full board of directors are available on the CBSA website.

About the Colorado BioScience Association

Colorado BioScience Association champions life science. We serve as the hub of Colorado’s thriving bioscience sector by connecting innovators to funding, infrastructure, research and talent. From promising young companies to established corporations and institutions, we provide opportunities for networking, education and professional development. We grow the bioscience workforce and lead business expansion policies to advance the industry in our state. CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers. Learn more about us at http://www.cobioscience.com.

Contacts

Colorado BioScience Association
Tom Borak, 720-382-5918
Communications and Membership Manager
tborak@cobioscience.com
or
Primavera Group for Colorado BioScience Association
Sheliah Reynolds, 720-289-4739
sheliah@theprimaveragroup.com

Release Summary

Colorado BioScience Association announces new board members. Scott Larson, Terumo BCT General Counsel, named chairman of the board.

Contacts

Colorado BioScience Association
Tom Borak, 720-382-5918
Communications and Membership Manager
tborak@cobioscience.com
or
Primavera Group for Colorado BioScience Association
Sheliah Reynolds, 720-289-4739
sheliah@theprimaveragroup.com